Industry experts discuss how to address extractables and leachables in single-use systems and the challenges in qualifying equipment.
BioPharm International spoke with Andrew Bulpin, head of process solutions for MilliporeSigma; Danny Hower, extractables & leachables supervisor, SGS; Dr. Dujuan Lu, extractables & leachables technical client manager, SGS; Helene Pora, vice-president, technical communication and regulatory strategy, Pall Biotech; Eric Isberg, director of Life Sciences at Entegris; and experts from the Bio-Process Systems Alliance (BPSA) Technical Committee, about managing quality and extractables and leachables (E&L) in single-use systems.
Read this article in the BioPharm International Single-Use Systems 2018 eBook.
BioPharm International
eBook: Single-Use Systems
Vol. 31
June 2018
Pages: 24–29
When referring to this article, please cite it as S. Haigney, "Managing Quality in Single-Use Systems," BioPharm International Single-Use Systems eBook (June 2018).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.